• The initiative Bovihealth aims the development of peptides to be used as health and growth promoter in cattle.
  • Besides Bionaturis Group, Bovihealth also has the Sociedad Cooperativa Andaluza Ganadera del Valle de los Pedroches (COVAP) as a partner.


Jerez de la Frontera, 24st of July, 2015. Corporacion Tecnologica de Andalucia (CTA) has granted the Company with an incentive worth of €147.027,46 to partially fund the Bovihealth project. The initiative aims the development of peptides to be used as health and growth promoter in cattle. The Company partners up in this project with an end-user of the seek products, the Cooperativa del Valle de los Pedroches (COVAP). The incentive is completely subsidized by the Regional Andalusian Government and the Ministry of Economy and Competitiveness of Spain.

“With this initiative we intend to develop effective feeding treatments to boost the immune system of the cattle herd, improving the productivity index at the same time” explains Victor Infante, CEO of Bionaturis Group. “The approach points to reduce the use of traditional antibiotics as far as possible. To that end, we will test some peptides with proven successful activity in other type of livestock (swine, poultry)”

Two public research groups, the group BIO 155 of Analysis of biological macromolecules of interest in biomedicine, which belongs to the CSIC-Instituto López-Neyra, and the group AGR 137 of Animal Anatomical Pathology, of the University of Córdoba (UCO) also collaborate in the project.

About CTA

Corporacion Tecnologica de Andalucia is a private foundation, launched by the Junta of Andalusia and backed by 152 member companies, in order to promote regional innovation on the basis of transference. CTA is dedicated to financing R&D business projects in collaboration with Universities, and offers added services to innovative companies, universities, technological centers or entities that foster innovation, focused on converting the results of R&D into real business and wealth.

 About Bionaturis Group

Bionaturis Group offers the latest biotechnological products and services for human and animal health. Considered to be a world benchmark for vaccine development, Bionaturis ended the last financial year with a sales increase of 73% and a positive EBITDA of 29% compared to 2013. The biotechnological Group, which envisages a greater global access to health, is listed on the Spanish stock exchange for SMEs (ticker BNT).




For further information:

Bionaturis Press

Virginia Montero

+34 856 818 424 / 655 311047



Estudio de Comunicación

+ 34 91 576 52 50